Obermatt
See Similar Stocks →

Quest Diagnostics

NYQ:DGX · US74834L1008
Health Care Providers & ServicesX-Large

360

35
EV / EBIT48
Price / Owner Earnings31
Owner Earnings Yield70
Dividend Yield99
Price/Sales85
EV / Gross Profit27
Price/Book48
Return on Capital74
Cash Return on Capital65
Return on Equity78
EBIT Margin87
Gross Profitability37
Cash Conversion37
Accruals47
Owner Earnings Margin84
Sales growth64
Profit Growth98
Long-Term EPS Growth31
Owner Earnings Growth45
Reinvestment31
Price momentum41
Debt load23
Refinancing95
Debt Payback42
Liquidity90
Analyst ratings9
Opinion Changes50
Price Target Upside32
Market mood77
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Quest Diagnostics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
TypePublic Company
ExchangeNYSE
Founded1990
Employees18,272
Websitequestdiagnostics.com
ISINUS74834L1008
Last UpdateApr 2, 2026
Indices
S&P 500 (USA)D.J. US Health Care
Themes
Infectious DiseasesGeneticsArtificial IntelligenceMachine LearningChronic DiseasesHealth DiagnosticsNeurologyOncologyBiotechnologyHealth CareInformation ServicesPrecision Medicine

Description

Quest Diagnostics Incorporated (Quest Diagnostics) works across the healthcare ecosystem to create a healthier world. The company provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations…

Analysis

Middle-of-the-road

Quest Diagnostics Incorporated sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 20.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 9%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is adequate. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Flags to be aware of: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
93
2023202420252026

All-time high

93

Jun 2026

All-time low

30

Jan 2024

Average rank

71

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
85
16
20
34
Price/Earnings
7
44
61
54
Price/Book
48
38
50
71
Dividend Yield
99
90
95
92
Value (overall)
81
56
63
80

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Quest Diagnostics with its peers
Stoke Therapeutics
NSQ:STOK
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Labcorp
NYQ:LH
40
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Mistras
NYQ:MG
33
CountryUSA
IndustryProfessional Services
SizeMedium
Full Stock Analysis →
Masimo
NSQ:MASI
44
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Vor Biopharma
NSQ:VOR
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Adaptive Biotechnologies
NSQ:ADPT
20
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →